Latest news with #Inogen
Yahoo
24-05-2025
- Business
- Yahoo
Needham Upgrades Inogen (INGN) to Buy
On May 22, Needham analysts upped Inogen, Inc. (NASDAQ:INGN)'s stock from 'Hold' to 'Buy', offering a price objective of $12.00. The upgrade stems from the belief that the company's efforts under new management are not being given due weightage. Inogen, Inc. (NASDAQ:INGN), a medical technology company, has exhibited a return to positive mid-single-digit revenue growth. Notably, in Q1 2025, the company's total revenue came in at $82.3 million, reflecting a rise of 5.5% YoY, thanks to elevated demand trends from international and domestic business-to-business customers. A close-up of a medical technician wearing lab coat and a face mask preparing a portable oxygen concentrator for a patient. Needham analysts opine that the revenue growth is expected to accelerate in H2 2025 and into 2026. This positive outlook is backed by Inogen, Inc. (NASDAQ:INGN)'s improved margins and strategic steps adopted by management in a bid to diversify its portfolio into a broader respiratory device business. The diversification strategy is being regarded as a critical factor in Inogen, Inc. (NASDAQ:INGN)'s potential success. Total gross margin in Q1 2025 sat at 44.2%, implying an improvement of 15 bps as compared to 44.1% in the prior-year period. This was aided by lower warranty expense, which was partially offset by the impact of channel and customer mix. Overall, Needham's upgrade exhibits confidence in the company's turnaround strategy and growth prospects. While we acknowledge the potential of INGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than INGN and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Sign in to access your portfolio
Yahoo
22-05-2025
- Business
- Yahoo
Needham Upgrades Inogen (INGN) to Buy
On May 22, Needham analysts upped Inogen, Inc. (NASDAQ:INGN)'s stock from 'Hold' to 'Buy', offering a price objective of $12.00. The upgrade stems from the belief that the company's efforts under new management are not being given due weightage. Inogen, Inc. (NASDAQ:INGN), a medical technology company, has exhibited a return to positive mid-single-digit revenue growth. Notably, in Q1 2025, the company's total revenue came in at $82.3 million, reflecting a rise of 5.5% YoY, thanks to elevated demand trends from international and domestic business-to-business customers. A close-up of a medical technician wearing lab coat and a face mask preparing a portable oxygen concentrator for a patient. Needham analysts opine that the revenue growth is expected to accelerate in H2 2025 and into 2026. This positive outlook is backed by Inogen, Inc. (NASDAQ:INGN)'s improved margins and strategic steps adopted by management in a bid to diversify its portfolio into a broader respiratory device business. The diversification strategy is being regarded as a critical factor in Inogen, Inc. (NASDAQ:INGN)'s potential success. Total gross margin in Q1 2025 sat at 44.2%, implying an improvement of 15 bps as compared to 44.1% in the prior-year period. This was aided by lower warranty expense, which was partially offset by the impact of channel and customer mix. Overall, Needham's upgrade exhibits confidence in the company's turnaround strategy and growth prospects. While we acknowledge the potential of INGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than INGN and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-05-2025
- Business
- Yahoo
What Makes Inogen (INGN) a New Buy Stock
Investors might want to bet on Inogen (INGN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time. Therefore, the Zacks rating upgrade for Inogen basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock. For Inogen, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher. As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>. For the fiscal year ending December 2025, this produces oxygen concentrators for patients suffering from chronic respiratory conditions is expected to earn -$1.15 per share, which is a change of 24.3% from the year-ago reported number. Analysts have been steadily raising their estimates for Inogen. Over the past three months, the Zacks Consensus Estimate for the company has increased 22.5%. Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. You can learn more about the Zacks Rank here >>> The upgrade of Inogen to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inogen, Inc (INGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
Inogen to Report First Quarter 2025 Financial Results on May 7, 2025
GOLETA, Calif., April 16, 2025--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. This webcast will also be archived on the website for 6 months. A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through May 14, 2025. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13752582. Inogen has used, and intends to continue to use, its Investor Relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. About Inogen Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease. For more information, please visit View source version on Contacts ir@
Yahoo
20-03-2025
- Business
- Yahoo
Inogen To Present at 24th Annual Needham Virtual Healthcare Conference
GOLETA, Calif., March 20, 2025--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 24th Annual Needham Virtual Healthcare Conference. Kevin Smith, President and Chief Executive Officer, and Michael Bourque, Chief Financial Officer, are scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. About Inogen Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease. For more information, please visit View source version on Contacts ir@
